Liquidia Corporation (LQDA) is a Healthcare stock trading at $66.75 (as of 2026-09-11), with a market capitalization of $5.97B and a trailing P/E of 43.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Understand Liquidia Corporation: how it makes money
Liquidia makes YUTREPIA, an inhaled dry powder treprostinil inhaler for pulmonary arterial hypertension, plus generic treprostinil injection, sold through US specialty channels. Revenue is concentrated in one product serving a small patient population, with L606 in Phase 3 as the next engine.
One patented inhaler for a rare lung disease generates a 50% operating margin because each patient has no oral alternative and the proprietary delivery device locks them into ongoing refills.
Business quality (Exceptional): Exceptional margin profile (50% operating) on a single, still-growing product, but the P/E of 35.6x sits 108% above the pharmaceutical products average of 17.1x, leaving little room for execution slips.
Valuation: At 36× earnings, LQDA trades 108% above the Pharmaceutical Products average (17×).
Bull case
Path to $1B revenue: Management projects more than $1 billion in net revenue in 2027, up from roughly $800M annualized at the $200M quarterly run rate. That implies the patient base roughly doubles again, which the 4,500 unique prescriptions today suggest is still early in the adoption curve.
Outpacing the inhaled market: YUTREPIA's growth exceeded total inhaled treprostinil market growth (latest_call), meaning Liquidia is taking share rather than simply riding a growing category. In a niche PAH market, share gains compound quickly and defend the 50% operating margin.
Fifty-percent margin engine: The 50% operating margin at $200M quarterly revenue (10-Q) shows the inhaler carries very low variable cost relative to its price point. As patient counts scale, fixed costs dilute further, pushing margins toward the cash-burn-free level management referenced on the call.
Bear case
R&D burn accelerates: R&D spending is expected to rise sharply in late 2026 and again in 2027 (latest_call) as L606 moves through Phase 3. That timing collides with the $1B revenue target, meaning the profit inflection may arrive later than the stock's 35.6x P/E implies.
Four-times-daily ceiling on uptake: YUTREPIA's four-times-daily regimen remains a commercial limitation (latest_call). In a disease where patients are already managing multiple therapies, convenience drives adherence; a competitor with a QD or BID inhaled option could erode the 85% prescription-to-start conversion.
Priced for flawless execution: At 35.6x trailing earnings versus a 17.1x pharmaceutical products industry average (108% above), the stock embeds the $1B target and continued outperformance. Any Phase 3 miss on L606 or a legal ruling imposing royalties would compress the multiple quickly.